Advancing bispecific antibodies

Antibodies that simultaneously target two distinct antigens overcome cancer therapy resistance by addressing antigenic diversity and diminished T cell action. 

Monoclonal antibodies and immunotherapy are potent cancer treatments, but preventing treatment resistance to these therapies is challenging. Monoclonal antibodies fail to engage T cells for sustained antitumor immunity, and immunotherapy does not account for antigen variation across malignant cells. Bispecific antibodies offer a solution by bolstering T cell action against cancer cells and simultaneously targeting distinct antigens. In this webinar, George Weiner will discuss combining anticancer monoclonal and bispecific antibodies to enhance T cell help, and Mohamed-Reda Benmebarek will delve into using adaptable, bispecific antibodies to address antigen variability while ensuring sustained clinical efficacy.

Topics to be covered

  • Exploiting the synergistic power of bispecific and monoclonal antibodies 
  • Developing bispecific antibodies for modular and controllable cancer therapy

Tuesday, February 6th, 2023 | 2:30 PM - 4:00 PM Eastern Time
This webinar will be available to view live and on demand.


George Weiner, MD

George Weiner, MD

University of Iowa

Mohamed-Reda Benmebarek, PhD

Mohamed-Reda Benmebarek, PhD

Postdoctoral Fellow
National Cancer Institute

Supported by